West Pharmaceutical Services (WST) Accumulated Expenses (2009 - 2026)

West Pharmaceutical Services (WST) has reported Accumulated Expenses for 18 consecutive years, with $97.1 million the latest figure, recorded in Q2 2026.

• Quarterly Accumulated Expenses rose 3.96% year-over-year to $97.1 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $97.1 million (up 3.96% YoY) and the FY2025 annual result came in at $135.9 million, up 84.9% from the prior year.
• Accumulated Expenses improved to $97.1 million in Q2 2026 per WST's latest filing, from $72.6 million in the prior quarter.
• Over the last five years, Accumulated Expenses for WST reached as high as $135.9 million in Q4 2025 and fell as low as $65.7 million in Q1 2023.
• A 5-year average of $84.9 million and a median of $79.2 million in 2022 frame the typical range for Accumulated Expenses.
• Annual changes were most pronounced in 2022 — Accumulated Expenses sank 41.49% — and 2025, when it surged 84.9%.
• Year by year, Accumulated Expenses stood at $76.8 million in 2022, then soared by 37.89% to $105.9 million in 2023, then slumped by 30.59% to $73.5 million in 2024, then jumped by 84.9% to $135.9 million in 2025, then fell by 28.55% to $97.1 million in 2026.
• According to Business Quant data, Accumulated Expenses over the past three periods registered $97.1 million, $72.6 million, and $135.9 million for Q2 2026, Q1 2026, and Q4 2025 respectively.